Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Kalinsky on Initial Results of the RxPONDER Trial in HR+/HER2- Breast Cancer

December 9th 2020

Kevin Kalinsky, MD, MS, discusses the initial results of the phase 3 RxPONDER trial in patients with hormone receptor–positive, HER2-negative breast cancer.

AI-Digital Breast Cancer Risk Assessment Platform Accurately Classifies Low-Risk Recurrence Scores

December 9th 2020

December 9, 2020 - The artificial intelligence–digital breast cancer risk discrimination platform PreciseDx was able to classify patients with Oncotype Dx low-risk recurrence scores with high accuracy using only hematoxylin and eosin stain images and limited clinical data.

Tumor Subtype Can Be a Prognostic Marker for Patients Treated with Ribociclib

December 9th 2020

December 9, 2020 - Intrinsic tumor subtype was found to be associated with prognosis in patients with hormone receptor–positive, HER2-negative advance breast cancer who received the CDK4/6 inhibitor ribociclib.

Women Who Undergo Mastectomy with Reconstruction At Higher Risk for Chronic Controlled Substance Use

December 9th 2020

December 9, 2020 - Among women who underwent a mastectomy plus reconstructive surgery, those who received a breast cancer diagnosis, received chemotherapy and were younger were reported to have a higher risk of new chronic controlled substance use.

Serial Circulating Tumor Cell Enumeration Predicts OS in Metastatic Breast Cancer

December 9th 2020

December 9, 2020 - Follow-up circulating tumor cell assessments were confirmed to strongly predict overall survival outcomes in patients with metastatic breast cancer, when performed at a median of 29 days following treatment initiation.

Symptoms Under-Recognized in Patients Who Receive Radiotherapy After Lumpectomy

December 9th 2020

December 8, 2020 - Oncologists widely under-recognize substantial symptoms in patients with breast cancer receiving radiotherapy after undergoing a lumpectomy, highlighting a need to improve symptom detection.

Menopausal Status May Inform Need for Chemotherapy in Lymph Node+, HR+/HER2- Breast Cancer

December 9th 2020

The addition of chemotherapy to endocrine therapy led to an improvement in 5-year invasive disease-free survival and overall survival in premenopausal but not postmenopausal women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer and a recurrence score between 0 and 25.

Abemaciclib Continues to Show Reduced Risk in iDFS in High-Risk Early HR+ Breast Cancer

December 9th 2020

December 9, 2020 - The combination of abemaciclib and standard endocrine therapy showed a 28.7% reduction in the risk of invasive disease recurrence or death compared with endocrine therapy alone in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

Dr. Edith Mitchell Elected to Fellowship in the Royal College of Physicians of London

December 7th 2020

Edith P. Mitchell, MD, FACP, FCPP, FRCP, Associate Director for Diversity Affairs at the Sidney Kimmel Cancer Center – Jefferson Health, has been recognized as a fellow of the Royal College of Physicians of London.

Dr. Rugo on the Significance of Becoming a Giant in Cancer Care

December 3rd 2020

Hope S. Rugo, MD, discusses the significance of becoming a Giant of Cancer Care®.

Dr. Patt on the Role of Sacituzumab Govitecan in TNBC

December 3rd 2020

Debra Patt, MD, PhD, MBA, breast medical oncologist, vice president of Texas Oncology, highlights the role of sacituzumab govitecan-hziy in triple-negative breast cancer.

Overcoming Mechanisms of Resistance to CDK4/6, PI3K Inhibition in Breast Cancer

December 3rd 2020

Cynthia X. Ma, MD, PhD, discusses several research efforts examining mechanisms of resistance to CDK4/6 and PI3K inhibitors in breast cancer and some of the novel combinations that may possess the potential to overcome this challenge.

Need for Genetic Testing Becomes More Pronounced in Breast, Gynecologic Cancers as Targeted Approaches Abound

December 2nd 2020

Lan G. Coffman, MD, PhD, discusses the role of genetic testing in breast and gynecologic cancers and the many advances made with targeted therapies.

Pivotal Trials Lead to Transformative Approaches in HER2+ Breast Cancer

December 2nd 2020

December 2, 2020 - Four pivotal trials––KATHERINE, FeDeriCa, DESTINY-Breast01, and HER2CLIMB have not only amplified the armamentarium in HER2-positive breast cancer, but have illustrated the importance of neoadjuvant therapy, alternative administration methods, high-potency HER2-targeted therapy, and inclusion of all-comers with brain metastases in clinical trials.

Bardia Brings Clinical Scenarios to Light Across Breast Cancer Subtypes

November 30th 2020

The availability of targeted therapy, antibody-drug conjugates, and immunotherapy necessitates greater discussions regarding second-line treatment for patients with metastatic hormone receptor–positive, HER2-negative breast cancer, third-line treatment for patients with metastatic HER2-positive breast cancer, and neoadjuvant therapy for patients with locally advanced triple-negative breast cancer.

Investigators Take Stock of New Landscape for Metastatic HER2-Positive Breast Cancer

November 26th 2020

Breast cancer specialists discuss noteworthy data on efficacy and safety about fam-trastuzumab deruxtecan-nxki, neratinib, and tucatinib.

Dr. Opyrchal on the Current State of Biomarkers in TNBC

November 24th 2020

Mateusz Opyrchal, MD, PhD, discusses the current state of biomarkers in triple-negative breast cancer.

Treatment Selection Becomes Complex Amid Growing Armamentarium in HER2+ Breast Cancer

November 24th 2020

Nusayba Bagegni, MD, discusses prominent data that have emerged in early-stage and metastatic HER2-positive breast cancer.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

Standardized Frontline CDK4/6 Inhibition Sets the Stage for Further Research in HR+/HER2- Breast Cancer

November 23rd 2020

November 23, 2020 — Katherine K. Clifton, MD, discusses the utility of CDK4/6 inhibitors as frontline treatment for patients with HR-positive/HER2-negative breast cancer, the growing role of PI3K inhibitors in this space, and potential future research directions with these treatments.